These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 29909153)

  • 61. Neurologic complications after allogeneic hematopoietic stem cell transplantation in children: analysis of prognostic factors.
    Kang JM; Kim YJ; Kim JY; Cho EJ; Lee JH; Lee MH; Lee SH; Sung KW; Koo HH; Yoo KH
    Biol Blood Marrow Transplant; 2015 Jun; 21(6):1091-8. PubMed ID: 25708217
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Early blood stream infection following allogeneic hematopoietic stem cell transplantation is a risk factor for acute grade III-IV GVHD in children and adolescents.
    Sano H; Hilinski JA; Qayed M; Applegate K; Newton JG; Watkins B; Chiang KY; Horan J
    Pediatr Blood Cancer; 2018 Feb; 65(2):. PubMed ID: 28921804
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Association between acute graft versus host disease and lung injury after allogeneic haematopoietic stem cell transplantation.
    Liu QF; Luo XD; Ning J; Xu D; Fan ZP; Sun J; Zhang Y; Xu B; Wei YQ
    Hematology; 2009 Apr; 14(2):63-72. PubMed ID: 19298716
    [TBL] [Abstract][Full Text] [Related]  

  • 64. High incidence of invasive aspergillosis associated with intestinal graft-versus-host disease following nonmyeloablative transplantation.
    Labbé AC; Su SH; Laverdière M; Pépin J; Patiño C; Cohen S; Kiss T; Lachance S; Sauvageau G; Busque L; Roy DC; Roy J
    Biol Blood Marrow Transplant; 2007 Oct; 13(10):1192-200. PubMed ID: 17889356
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Cytogenetics and comorbidity predict outcomes in older myelodysplastic syndrome patients after allogeneic stem cell transplantation using reduced intensity conditioning.
    Yucel OK; Saliba RM; Rondon G; Ahmed S; Alousi A; Bashir Q; Ciurea SO; Popat U; Khouri I; Marin D; Rezvani K; Kebriaei P; Shpall EJ; Champlin RE; Oran B
    Cancer; 2017 Jul; 123(14):2661-2670. PubMed ID: 28324640
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Risk of graft-versus-host disease with rituximab-containing conditioning regimens in allogeneic hematopoietic stem cell transplant.
    Marini BL; Markstrom D; Frame D
    J Oncol Pharm Pract; 2017 Jun; 23(4):255-263. PubMed ID: 26970572
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Long-term prognosis for 1-year relapse-free survivors of CD34+ cell-selected allogeneic hematopoietic stem cell transplantation: a landmark analysis.
    Cho C; Hsu M; Barba P; Maloy MA; Avecilla ST; Barker JN; Castro-Malaspina H; Giralt SA; Jakubowski AA; Koehne G; Meagher RC; O'Reilly RJ; Papadopoulos EB; Ponce DM; Tamari R; van den Brink MRM; Young JW; Devlin SM; Perales MA
    Bone Marrow Transplant; 2017 Dec; 52(12):1629-1636. PubMed ID: 28991247
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and Rituximab Is Associated with Improved Outcomes Compared with Fludarabine and Busulfan after Allogeneic Stem Cell Transplantation for B Cell Malignancies.
    Kennedy VE; Savani BN; Greer JP; Kassim AA; Engelhardt BG; Goodman SA; Sengsayadeth S; Chinratanalab W; Jagasia M
    Biol Blood Marrow Transplant; 2016 Oct; 22(10):1801-1807. PubMed ID: 27377900
    [TBL] [Abstract][Full Text] [Related]  

  • 69. G-CSF-primed haplo-identical HSCT with intensive immunosuppressive and myelosuppressive treatments does not increase the risk of pre-engraftment bloodstream infection: a multicenter case-control study.
    Ren J; Lin Q; Chen W; Lin C; Zhang Y; Chen C; Chen S; Yuan X; Chen P; Luo X; Lin Y; Shen L; Guo M; Chen Q; Xiao M; Chen Y; Wu X; Zeng Y; Chen Z; Ma X; Hu J; Yang T
    Eur J Clin Microbiol Infect Dis; 2019 May; 38(5):865-876. PubMed ID: 30685808
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Cecum ulcer is a reliable endoscopic finding in cytomegalovirus colitis concomitant with graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
    Matsuda K; Ono S; Ishikawa M; Miyamoto S; Abiko S; Tsuda M; Yamamoto K; Kudo T; Shimizu Y; Hayase E; Hashimoto D; Teshima T; Matsuno Y; Sakamoto N
    Ann Hematol; 2018 May; 97(5):877-883. PubMed ID: 29340759
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Does anti-thymocyte globulin have a place in busulfan/fludarabine conditioning for matched related donor hematopoietic stem cell transplantation?
    Ji YS; Lee MS; Min CW; Park SK; Kim SH; Yun J; Kim HJ; Kim KH; Kim CK; Lee KT; Won JH; Hong DS
    Korean J Intern Med; 2016 Jul; 31(4):750-61. PubMed ID: 27017944
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Healthcare Burden, Risk Factors, and Outcomes of Mucosal Barrier Injury Laboratory-Confirmed Bloodstream Infections after Stem Cell Transplantation.
    Dandoy CE; Haslam D; Lane A; Jodele S; Demmel K; El-Bietar J; Flesch L; Myers KC; Pate A; Rotz S; Daniels P; Wallace G; Nelson A; Waters H; Connelly B; Davies SM
    Biol Blood Marrow Transplant; 2016 Sep; 22(9):1671-1677. PubMed ID: 27311966
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The incidence, risk factors and outcomes of early bloodstream infection in patients with malignant hematologic disease after unrelated cord blood transplantation: a retrospective study.
    Ge J; Yang T; Zhang L; Zhang X; Zhu X; Tang B; Wan X; Tong J; Song K; Yao W; Sun G; Sun Z; Liu H
    BMC Infect Dis; 2018 Dec; 18(1):654. PubMed ID: 30545330
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Allogeneic hematopoietic stem cell transplantation (HSCT) after reduced intensity conditioning.
    Servais S; Baron F; Beguin Y
    Transfus Apher Sci; 2011 Apr; 44(2):205-10. PubMed ID: 21345734
    [TBL] [Abstract][Full Text] [Related]  

  • 75. High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma.
    Law LY; Horning SJ; Wong RM; Johnston LJ; Laport GG; Lowsky R; Shizuru JA; Blume KG; Negrin RS; Stockerl-Goldstein KE
    Biol Blood Marrow Transplant; 2006 Jul; 12(7):703-11. PubMed ID: 16785059
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Acute GVHD is a strong predictor of full donor CD3+ T cell chimerism after reduced intensity conditioning allogeneic stem cell transplantation.
    El-Cheikh J; Vazquez A; Crocchiolo R; Furst S; Calmels B; Castagna L; Lemarie C; Granata A; Ladaique P; Oudin C; Faucher C; Chabannon C; Blaise D
    Am J Hematol; 2012 Dec; 87(12):1074-8. PubMed ID: 22911907
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Bloodstream infection after stem cell transplantation in children with idiopathic aplastic anemia.
    Kobayashi R; Yabe H; Kikuchi A; Kudo K; Yoshida N; Watanabe K; Muramatsu H; Takahashi Y; Inoue M; Koh K; Inagaki J; Okamoto Y; Sakamaki H; Kawa K; Kato K; Suzuki R; Kojima S
    Biol Blood Marrow Transplant; 2014 Aug; 20(8):1145-9. PubMed ID: 24727336
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Allogeneic stem cell transplantation as treatment for heavily treated, refractory acute graft-versus-host disease after HLA-mismatched stem cell transplantation.
    Ikegame K; Yoshihara S; Taniguchi Y; Kaida K; Inoue T; Okada M; Taniguchi K; Hasei H; Tamaki H; Fujioka T; Kato R; Soma T; Ogawa H
    Exp Hematol; 2011 Aug; 39(8):880-90. PubMed ID: 21689724
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Prophylaxis with sirolimus and tacrolimus ± antithymocyte globulin reduces the risk of acute graft-versus-host disease without an overall survival benefit following allogeneic stem cell transplantation.
    Rosenbeck LL; Kiel PJ; Kalsekar I; Vargo C; Baute J; Sullivan CK; Wood L; Abdelqader S; Schwartz J; Srivastava S; Abonour R; Robertson MJ; Nelson RP; Cornetta K; Fausel CA; Farag SS
    Biol Blood Marrow Transplant; 2011 Jun; 17(6):916-22. PubMed ID: 20932925
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Rituximab-containing reduced-intensity conditioning improves progression-free survival following allogeneic transplantation in B cell non-Hodgkin lymphoma.
    Epperla N; Ahn KW; Ahmed S; Jagasia M; DiGilio A; Devine SM; Jaglowski S; Kennedy V; Rezvani AR; Smith SM; Sureda A; Fenske TS; Kharfan-Dabaja MA; Armand P; Hamadani M
    J Hematol Oncol; 2017 Jun; 10(1):117. PubMed ID: 28606176
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.